Pharmacokinetics and safety of a new paediatric fixed-dose combination of zidovudine/lamivudine/nevirapine in HIV-infected children.
about
Estimating age-based antiretroviral therapy costs for HIV-infected children in resource-limited settings based on World Health Organization weight-based dosing recommendationsFormulations for children: problems and solutionsNevirapine exposure with WHO pediatric weight band dosing: enhanced therapeutic concentrations predicted based on extensive international pharmacokinetic experience.Plasma pharmacokinetics of once-daily abacavir- and lamivudine-containing regimens and week 96 efficacy in HIV-infected Thai childrenPopulation pharmacokinetics study of recommended zidovudine doses in HIV-1-infected childrenPharmacokinetics of zidovudine dosed twice daily according to World Health Organization weight bands in Ugandan HIV-infected children.The role of formulation on the pharmacokinetics of antiretroviral drugs.Dose evaluation of lamivudine in human immunodeficiency virus-infected children aged 5 months to 18 years based on a population pharmacokinetic analysis.Pharmacokinetics of antiretroviral drug varies with formulation in the target population of children with HIV-1.A model-based approach for the evaluation of once daily dosing of lamivudine in HIV-infected children.Optimization of the strength of the efavirenz/lamivudine/abacavir fixed-dose combination for paediatric patients.Sub-therapeutic nevirapine concentration during antiretroviral treatment initiation among children living with HIV: Implications for therapeutic drug monitoring.Effect of Sorbitol on the Pharmacokinetic Profile of Lamivudine Oral Solution in Adults: An Open-Label, Randomized Study.
P2860
Q33611392-D587FDB9-A10F-47AD-B23E-57237054D214Q35135943-D6CB5ABB-9CD5-44B6-B256-EDC7E2DFCD38Q36276839-9BDFF9A0-C2FB-42D6-A778-2B547E362798Q37098376-AC035C03-D8C7-4F5F-A7A1-D8E410E1236DQ37263890-E4CE21D4-0435-43AB-B37E-5F8A9BE1B546Q37708677-888ACE00-7B66-42B8-B6A0-FC4F246F3D13Q38216047-0398DE92-A5D5-4E82-A913-BCBD47C6C118Q38771392-008E5A0A-7741-4BBB-A47A-699C83853EAEQ38868724-C02F2F0F-4629-477E-ACC8-28E41830A32AQ39051618-5FA54462-81C4-4616-BB34-2D183793E445Q39231462-8CE70743-9336-4B2F-B8B5-9ED313C99356Q40075886-C8325408-E2F2-455A-B769-64BD498FCAD9Q49908214-313DE90F-EFE4-4942-86C1-A6234485DEF9
P2860
Pharmacokinetics and safety of a new paediatric fixed-dose combination of zidovudine/lamivudine/nevirapine in HIV-infected children.
description
2011 nî lūn-bûn
@nan
2011年の論文
@ja
2011年論文
@yue
2011年論文
@zh-hant
2011年論文
@zh-hk
2011年論文
@zh-mo
2011年論文
@zh-tw
2011年论文
@wuu
2011年论文
@zh
2011年论文
@zh-cn
name
Pharmacokinetics and safety of ...... pine in HIV-infected children.
@ast
Pharmacokinetics and safety of ...... pine in HIV-infected children.
@en
type
label
Pharmacokinetics and safety of ...... pine in HIV-infected children.
@ast
Pharmacokinetics and safety of ...... pine in HIV-infected children.
@en
prefLabel
Pharmacokinetics and safety of ...... pine in HIV-infected children.
@ast
Pharmacokinetics and safety of ...... pine in HIV-infected children.
@en
P2093
P2860
P356
P1433
P1476
Pharmacokinetics and safety of ...... pine in HIV-infected children.
@en
P2093
Achara Eksaengsri
Bill Kabat
Chaiwat Ngampiyaskul
Chanin Limwongse
Edmund Capparelli
IMPAACT P1069 Team
Kenneth McIntosh
Kulkanya Chokephaibulkit
Linda Aurpibul
MariPat Toye
P2860
P304
P356
10.3851/IMP1931
P577
2011-01-01T00:00:00Z